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Abstract
Objectives. Osteoarthritis (OA) is the most common form of
arthritis characterised by cartilage degradation, synovitis and pain.
Disease modifying treatments for OA are not available. The critical
unmet need is to find therapeutic targets to reduce both disease
progression and pain. The cytokine IL-33 and its receptor ST2 have
been shown to play a role in immune and inflammatory diseases,
but their role in osteoarthritis is unknown. Methods. Non-OA and
OA human chondrocytes samples were examined for IL-33 and ST2
expression. Novel inducible cartilage specific knockout mice (IL-
33Acan CreERT2) and inducible fibroblast-like synoviocyte knockout
mice (IL-33Col1a2 CreERT2) were generated and subjected to an
experimental OA model. In addition, wild-type mice were intra-
articularly administered with either IL-33- or ST2-neutralising
antibodies during experimental OA studies. Results. IL-33 and its
receptor ST2 have increased expression in OA patients and a
murine disease model. Administering recombinant IL-33 increased
OA and pain in vivo. Synovial fibroblast-specific deletion of IL-33
decreased synovitis but did not impact disease outcomes, whilst
cartilage-specific deletion of IL-33 improved disease outcomes
in vivo. Blocking IL-33 signalling also reduced the release of
cartilage-degrading enzymes in human and mouse chondrocytes.
Most importantly, we show the use of monoclonal antibodies
against IL-33 and ST2 attenuates both OA and pain in vivo.
Conclusion. Overall, our data reveal blockade of IL-33 signalling as
a viable therapeutic target for OA.
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INTRODUCTION
Osteoarthritis (OA) is the most common form of
arthritis.1 There are no effective therapeutic
options for OA, and joint replacement still
remains the only approach to treat the disease.1
There is an urgent need to find suitable drug
targets to address both disease pathogenesis and
pain. Increased joint inflammation caused by
cytokines such as IL-1 and TNF-a has been shown
to drive OA pathogenesis.2,3 These cytokines
increase the production of proteases by
chondrocytes, the only resident cells in cartilage,
to cause cartilage degradation and secondary
disease symptoms such as pain.4 Monoclonal
antibodies targeting IL-1 and TNF-a and their
respective receptors have showed poor efficacy as
OA therapies.5,6 Hence, other key cytokines
responsible for OA pathogenesis that may be
effective drug targets still remain elusive.
IL-33, a member of the IL-1 family, plays a role
in both innate and adaptive immunity.7 IL-33
exerts its activity by binding to its specific primary
receptor ST2.8 Targeting both IL-33 and ST2
demonstrated protective effects in respiratory
diseases,9-11 skin diseases,12,13 kidney disease14,15
and neurological autoimmune pathologies.16,17 IL-
33 and ST2 concentrations were also found to be
increased in sera and synovial fluid of rheumatoid
arthritis (RA) patients.18,19 Blocking ST2 improved
experimental RA.20 However, the role of IL-33 in
OA is unknown. Using human and murine models,
we investigate whether IL-33 signalling is involved
in OA pathogenesis and the potential for
Figure 1. Increased levels of IL-33 and ST2 in human and murine OA. IL-33 concentration (pg mL1) in (a) SF and (b) serum of non-OA (n = 12)
and OA patients (n = 12). (c, d) mRNA and (e) protein expression of IL-33 and ST2 in isolated human chondrocytes from non-OA (n = 12) and
OA patients (n = 12). (f, g) OARSI scoring of cartilage tissue of sham-operated (n = 20) or DMM-operated (n = 20) WT mice (12 weeks post-
surgery end timepoint). (h) IL-33 concentration (pg mL1) in SF of sham-operated (n = 12) or DMM-operated (n = 12) WT mice (12 weeks post-
surgery end timepoint). (i, j) mRNA expression of IL-33 and ST2 in whole knee joints from sham-operated (n = 20) or DMM-operated (n = 20)
WT mice (12 weeks post-surgery end timepoint). All RT-qPCR gene expressions were normalised to the endogenous level of 18 s in respective
groups. Data are expressed as mean  S.E.M. with unpaired 2-tailed Student’s t-tests. n indicates the number of human specimens or mice per
group. NS = non-significant. P < 0.0001 is represented as ****.
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targeting the cytokines signalling
pharmacologically. In this study, we show IL-33
and ST2 levels are increased in OA patients. For
the first time, we demonstrate chondrocyte-
specific IL-33 production not synovial fibroblast-
specific IL-33 production is responsible for OA
pathogenesis in vivo. Finally, we demonstrate
blocking IL-33 signalling reduces the production
of proteases by human and murine chondrocytes
and attenuates OA and pain in vivo.
RESULTS
Increased levels of IL-33 and ST2 in human
and murine OA
We examined patient serum and SF to investigate
whether IL-33 signalling is involved in OA. IL-33
concentration was increased in SF, but not in sera,
of OA patients compared to non-OA patients
(Figure 1a and b). We also observed increased
mRNA and protein expression of IL-33 and ST2 in
isolated chondrocytes from OA patients compared
to non-OA patients (Figure 1c–e). We went on to
investigate whether IL-33 and ST2 levels are
elevated in murine OA (Figure 1f, g and
Supplementary figure 1a, b). Previous gene
expression studies did not show any change in IL-
33 or ST2 gene expression at early time points
post-surgery in mouse models of OA.21-23 Hence,
we used a later time point of 12 weeks post-DMM
surgery for our end-point readouts. IL-33
concentration was increased in SF, but not serum,
of mice with confirmed OA (Figure 1h and
Supplementary figure 1c). In addition, expression
of IL-33 and ST2 was increased in knee joints of
mice with OA compared to mice without OA
(Figure 1i and j and Supplementary figure 1d).
Increasing IL-33 levels exacerbates OA
in vivo
We wanted to elucidate the outcome of elevating
IL-33 in human chondrocytes. Isolated
chondrocytes treated with rIL-33 displayed
elevated mRNA and protein expression of
cartilage-degrading proteases (MMP-13, MMP-3
and ADAMTS-5) and decreased levels of
chondrogenic markers (COL2A1, SOX-9 and
Aggrecan) compared to cells treated with PBS
(Figure 2a and b). Isolated chondrocytes treated
with rIL-33 also displayed increased release of
MMP-13 and MMP-3 (Figure 2c and d). After these
observations, we administered rIL-33 in mice and
then performed DMM surgery to confirm whether
elevated levels of IL-33 may be responsible for
increased OA. Mice administered with rIL-33
demonstrated increased cartilage degradation,
synovitis, osteophyte maturity and pain compared
to mice treated with PBS (Figure 2e–i and
Supplementary figure 2a). In addition, mice
administered with rIL-33 had increased mRNA and
protein levels of cartilage-degrading proteases
and lowered mRNA and protein levels of
chondrogenic markers compared to mice treated
with PBS (Figure 2j and Supplementary figure 2b,
c); the same response as observed in human
chondrocytes treated with rIL-33.
Synovial fibroblast-specific ablation of IL-33
decreases synovitis but does not affect
cartilage degradation or pain
Previous studies have showed IL-33 to be
produced by synovial fibroblasts in RA.18,19 Hence,
we wanted to investigate whether ablating IL-33
in synovial fibroblasts will affect OA progression
in vivo. We successful generated synovial
fibroblast-specific IL-33 conditional KO mice (IL-
33COL1A2 Cre-ERT2; Supplementary figure 3a, b) and
induced OA in these mice using the DMM model.
IL-33COL1A2 Cre-ERT2 mice displayed decreased
synovitis, but there was no significant change in
cartilage degradation or pain outcomes compared
to IL-33fl/fl control mice (Figure 3a–e and
Supplementary figure 3c). There was no
significant difference in the expression of
cartilage-degrading proteases or chondrogenic
markers in IL-33COL1A2 Cre-ERT2 mice compared to
IL-33fl/fl control mice (Figure 3f and
Supplementary figure 3d, e). Surprised by these
results, we examined whether IL-33 expression
was changed in whole knee joints of IL-33COL1A2
Cre-ERT2 mice with OA. Whole knee joints with OA
displayed no change in IL-33 expression in IL-
33COL1A2 Cre-ERT2 compared to IL-33fl/fl control mice
(Supplementary figure 3f). This led us to
hypothesise that the increased IL-33 expression
seen in OA joints may come from chondrocytes.
Cartilage-specific ablation of IL-33 decreases
cartilage degradation, synovitis and pain
We next successfully generated cartilage-specific
IL-33 conditional KO mice (IL-33Acan Cre-ERT2;
Supplementary figure 4a, b) to investigate
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Figure 2. Increasing IL-33 levels exacerbates OA in vivo. (a) protein and (b) mRNA expression of cartilage-degrading proteases (MMP-13,
ADAMTS-5 and MMP-3) and chondrogenic markers (COL2A1, SOX-9 and Aggrecan) in isolated human chondrocytes from Non-OA (n = 20) and
OA patients (n = 20) treated with either PBS (vehicle control) or rIL-33 (30 ng mL1, 24 h). (c) MMP-13 and (d) MMP-3 protein level in cell
media supernatants obtained from isolated human chondrocytes from Non-OA (n = 12) and OA patients (n = 12) treated with either PBS (vehicle
control) or rIL-33 (30 ng mL1; 24 h). (e, f) OARSI scoring of cartilage tissue, (g) synovitis scoring and (h) osteophyte maturity scoring of sham-
operated (n = 20) or DMM-operated (n = 20) WT mice (12 weeks post-surgery end timepoint) treated intraperitoneally with either PBS (vehicle
control) or rIL-33 (33 lg kg1; daily for 12 weeks post-surgery). (i) von Frey pain assessment of sham-operated (n = 20) or DMM-operated
(n = 20) WT mice (12 weeks post-surgery end timepoint) treated intraperitoneally with either PBS (vehicle control) or rIL-33 (33 lg kg1; daily for
12 weeks post-surgery). (j) mRNA expression of cartilage-degrading proteases (MMP-13, ADAMTS-5 and MMP-3) and chondrogenic markers
(COL2A1, SOX-9 and Aggrecan) in whole knee joints of DMM-operated (n = 20) WT mice (12 weeks post-surgery end timepoint) treated
intraperitoneally with either PBS (vehicle control) or rIL-33 (33 lg kg1; daily for 12 weeks post-surgery). All RT-qPCR gene expressions were
normalised to the endogenous level of 18 s in respective groups. Data are expressed as mean  S.E.M. with unpaired 2-tailed Student’s t-tests
(c, d), two-way analysis of variance followed by the Tukey-Kramer test (f, g, h), or repeated measures 2-way ANOVA with Bonferroni’s post hoc
tests was used to compare groups at each time point (i; DMM PBS vs DMM rIL-33). n indicates the number of human specimens or mice per
group. NS = non-significant. P < 0.01, P < 0.001 or P < 0.0001 are represented as **, *** or ****, respectively.
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whether IL-33 production from chondrocytes is
the main factor in driving OA. IL-33Acan Cre-ERT2
mice displayed decreased cartilage degradation,
synovitis and pain compared to IL-33fl/fl control
mice post-DMM surgery (Figure 4a–e and
Supplementary figure 4c). In addition, whole knee
joints of IL-33Acan Cre-ERT2 mice displayed decreased
expression of cartilage degrading proteases and
increased expression of chondrogenic markers in
IL-33Acan Cre-ERT2 mice compared to IL-33fl/fl control
mice post-DMM surgery (Figure 4f and
Supplementary figure 4d, e). We also observed a
significant reduction of IL-33 mRNA expression in
whole knee joints of IL-33Acan Cre-ERT2 mice
compared to IL-33fl/fl control mice post-DMM
surgery (Supplementary figure 4f), indicating IL-33
from chondrocytes mainly drives disease
progression in vivo.
Neutralising ST2 and IL-33 attenuates OA
We wanted to investigate whether blocking IL-33
signalling may attenuate OA in vivo. WT mice
treated with ST2-neutralising antibody
demonstrated decreased cartilage degradation,
synovitis and pain compared to IgG1-treated
control mice post-DMM surgery (Figure 5a–e and
Supplementary figure 5a). Neutralising ST2
Figure 3. Synovial fibroblast-specific ablation of IL-33 decreases synovitis but does not affect cartilage degradation or pain. (a, b) OARSI scoring
of cartilage tissue, (c) synovitis scoring and (d) osteophyte maturity scoring of sham-operated (n = 20) or DMM-operated (n = 20) IL-33fl/fl control
mice and IL-33COL1A2 Cre-ERT2 mice (12 weeks post-surgery end timepoint). (e) von Frey pain assessment of sham-operated (n = 20) or DMM-
operated (n = 20) IL-33fl/fl control mice and IL-33COL1A2 Cre-ERT2 mice (12 weeks post-surgery end timepoint). (f) mRNA expression of cartilage-
degrading proteases (MMP-13, ADAMTS-5 and MMP-3) and chondrogenic markers (COL2A1, SOX-9 and Aggrecan) in whole knee joints of
DMM-operated (n = 20) IL-33fl/fl control mice and IL-33COL1A2 Cre-ERT2 mice (12 weeks post-surgery end timepoint). All RT-qPCR gene expressions
were normalised to the endogenous level of 18 s in respective groups. Data are expressed as mean  S.E.M. with two-way analysis of variance
followed by the Tukey-Kramer test (b, c, d) or repeated measures 2-way ANOVA with Bonferroni’s post hoc tests was used to compare groups
at each time point (e; DMM IL-33fl/fl control mice vs DMM IL-33COL1A2 Cre-ERT2 mice). n indicates the number of human specimens or mice per
group. NS = non-significant. P < 0.0001 is represented as ****.
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reduced expression of cartilage degrading
proteases and increased expression of
chondrogenic markers in mice post-DMM surgery
(Figure 5f and Supplementary figure 5b, c) and in
isolated OA human chondrocytes treated with rIL-
33 (Figure 5g and h) compared to respective
controls. In addition, the increased release of
MMP-13 and MMP-3 induced by rIL-33 was
reduced with the treatment of aST2 in isolated
OA human chondrocytes compared to IgG1-
treated human OA chondrocytes (Figure 5i and j).
Finally, we used an IL-33-neutralising antibody
in mice post-DMM surgery. WT mice treated with
aIL-33 displayed decreased cartilage degradation,
synovitis and pain compared to IgG1-treated
control mice post-DMM surgery (Figure 6a–e and
Supplementary figure 6a). aIL-33 treatment also
reduced expression of cartilage-degrading
proteases and increased expression of
chondrogenic markers in mice (Figure 6f and
Supplementary figure 6b, c) and isolated OA
human chondrocytes (Figure 6g and h) compared
to respective controls. The increased release of
MMP-13 and MMP-3 induced by rIL-33 in human
OA chondrocytes was also reduced by aIL-33
treatment (Figure 6i and j).
Figure 4. Cartilage-specific ablation of IL-33 decreases cartilage degradation, synovitis and pain. (a, b) OARSI scoring of cartilage tissue,
(c) synovitis scoring and (d) osteophyte maturity scoring of sham-operated (n = 20) or DMM-operated (n = 20) IL-33fl/fl control mice and
IL-33Acan Cre-ERT2 mice (12 weeks post-surgery end timepoint). (e) von Frey pain assessment of sham-operated (n = 20) or DMM-operated
(n = 20) IL-33fl/fl control mice and IL-33Acan Cre-ERT2 mice (12 weeks post-surgery end timepoint). (f) mRNA expression of cartilage-degrading
proteases (MMP-13, ADAMTS-5 and MMP-3) and chondrogenic markers (COL2A1, SOX-9 and Aggrecan) in whole knee joints of DMM-operated
(n = 20) IL-33fl/fl control mice and IL-33Acan Cre-ERT2 mice (12 weeks post-surgery end timepoint). All RT-qPCR gene expressions were normalised
to the endogenous level of 18 s in respective groups. Data are expressed as mean  S.E.M. with two-way analysis of variance followed by the
Tukey-Kramer test (b, c, d) or repeated measures 2-way ANOVA with Bonferroni’s post hoc tests was used to compare groups at each time point
(e; DMM IL-33fl/fl control mice vs DMM IL-33Acan Cre-ERT2 mice). n indicates the number of human specimens or mice per group. NS = non-
significant. P < 0.05, P < 0.001 or P < 0.0001 are represented as *, *** or ****, respectively.
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DISCUSSION
We have shown that IL-33 and ST2 are elevated in
human and murine OA. Increasing levels of IL-33
exacerbates disease in mice and in turn increases
the expression of cartilage degrading proteases
(MMP-13, MMP-3 and ADAMTS-5) and reduces
chondrogenic markers (COL2A1, SOX-9 and
Aggrecan). Interestingly, we also observed IL-33
production in an OA joint is mainly from
chondrocytes and not synovial fibroblasts. Most
importantly, we report that neutralising IL-33 and
ST2 reduces cartilage degradation and pain
in vivo.
Throughout our experiments, we observed
increasing IL-33 (via rIL-33) in turn increased the
expression and production of cartilage-degrading
proteases and reduced the expression of
chondrogenic markers in both human and
murine models. Vice versa decreasing IL-33
signalling in turn reduced the expression and
production of cartilage-degrading proteases and
increased the expression of prochondrogenic
markers in both human and murine models.
These strong correlations suggest IL-33 signalling
acts in the same manner as IL-1 and TNF-a
signalling to regulate cartilage proteases,
aggrecanases and matrix synthesis.3,24 We did not
investigate the mechanistic pathway of how IL-33
regulates these genes and proteins in
chondrocytes. However, Li and colleagues have
demonstrated double-stranded RNA released
from damaged articular chondrocytes increased
IL-33 expression via the TLR3/p38 pathway to
increase MMP-13 and MMP-3 production and
inhibit COL2A1 expression.25
The cell type responsible for IL-33 production in
an OA joint was of interest to us after observing
our initial findings of increased IL-33 expression in
OA patients. Palmer and colleagues showed IL-33
from synovial fibroblasts was important in RA
pathogenesis.20 Hence, we were surprised to
observe that synovial fibroblast-specific IL-33 KO
mice did not display significantly reduced IL-33
gene expression in whole knee joints post-DMM
surgery or have reduced disease outcomes
compared to control mice. Having observed this
result, we sought to investigate whether
chondrocytes were responsible for IL-33
production in an OA joint. Chondrocyte-specific
IL-33-deficient mice did display better disease
outcomes compared to control mice post-DMM
surgery. Moreover, IL-33 production in whole
knee joints of these mice was significantly
reduced compared to control mice. Together,
these results demonstrate that chondrocytes are
responsible for IL-33 production in an OA joint
and the immune response of IL-33 may be
different in RA and OA. This may suggest why the
use of anti-TNFa drugs in OA patients has not
been successful compared to the results seen in
RA patients.26
We also noticed synovial fibroblast-specific IL-33
KO mice showed reduced synovitis, but this did
not impact cartilage degradation, protease and
chondrogenic marker expression and pain post-
DMM surgery. This result raises an interestingly
larger question if the synovitis seen in an OA joint
driven by cytokines and cells in the synovium are
important in OA pathogenesis compared to the
cytokine production by chondrocytes. However,
further investigations on the crosstalk between IL-
33 and other cytokines and cell types in an OA
joint have to be conducted to answer this larger
question. It must be noted the COL1A2 Cre-ERT2
is not only synovial fibroblast specific but can also
be specific to dermal and visceral fibroblasts.27
However, we did not note any adverse effects in
these tissues. Currently, this is the only viable Cre-
ERT2 available to target synovium fibroblast cells;
hence, we used this murine tool in our
experiments.
The most important translational finding of our
study was that neutralising IL-33 and ST2
improved OA disease outcomes in vivo. IL-1 and
TNF-a have been extensively shown to be present
in an OA joint and to drive disease
pathogenesis.2,3 Past studies have tried to target
pro-inflammatory cytokines such as IL-1 and TNF-a
and their respective receptors for OA therapy but
showed poor efficacy. The shared common
cellular and intercellular pathways between IL-33
and IL-1 and TNF-a may suggest targeting IL-33
signalling is a possible new and better approach
to address OA. It must be noted we only used
systemic administration of both neutralising
antibodies because of the required daily dosing
regimen. Daily intra-articular injections of both
neutralising antibodies over a 12-week period in
itself caused joint damage hence were not
plausible to conduct in these studies. This may
suggest these drugs and reagents may have a
whole-body immune modulation, which may have
subsequent effect in the joint. In addition, we
only used the DMM model of OA. Using other
models such as the anterior cruciate ligament
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Figure 5. Neutralising ST2 attenuates OA. (a, b) OARSI scoring of cartilage tissue, (c) synovitis scoring and (d) osteophyte maturity scoring of
sham-operated (n = 20) or DMM-operated (n = 20) WT mice (12 weeks post-surgery end timepoint) treated intraperitoneally with either IgG1
(vehicle control; 50 µg per mouse; daily for 12 weeks post-surgery) or aST2 (50 µg per mouse; daily for 12 weeks post-surgery). (e) von Frey
pain assessment of sham- (n = 20) or DMM- (n = 20) operated WT mice (12 weeks post-surgery end timepoint) treated intraperitoneally with
either IgG1 (vehicle control; 50 µg per mouse; daily for 12 weeks post-surgery) or aST2 (50 µg per mouse; daily for 12 weeks post-surgery). (f)
mRNA expression of cartilage-degrading proteases (MMP-13, ADAMTS-5 and MMP-3) and chondrogenic markers (COL2A1, SOX-9 and
Aggrecan) in whole knee joints of DMM-operated (n = 20) treated intraperitoneally with either IgG1 (vehicle control; 50 µg per mouse; daily for
12 weeks post-surgery) or aST2 (50 µg per mouse; daily for 12 weeks post-surgery). (g) protein and (h) mRNA expression of cartilage degrading
proteases (MMP-13, ADAMTS-5 and MMP-3) and chondrogenic markers (COL2A1, SOX-9 and Aggrecan) in isolated human chondrocytes from
Non-OA (n = 20) and OA patients (n = 20) treated with rIL-33 (30 ng mL1, 24 h) and IgG1 (vehicle control; 3 lg mL1, 24 h) or aST2
(3 lg mL1, 24 h). (i) MMP-13 (j) MMP-3 protein level in cell media supernatants obtained from isolated human chondrocytes from Non-OA
(n = 12) and OA patients (n = 12) treated with rIL-33 (30 ng mL1; 24 h) and IgG1 (vehicle control; 3 lg mL1, 24 h) or aST2 (3 lg mL1,
24 h). All RT-qPCR gene expressions were normalised to the endogenous level of 18 s in respective groups. Data are expressed as
mean  S.E.M. with two-way analysis of variance followed by the Tukey-Kramer test (b, c, d) or repeated measures 2-way ANOVA with
Bonferroni’s post hoc tests was used to compare groups at each time point (e; DMM IgG1 control mice vs DMM aST2 mice) or with unpaired
2-tailed Student’s t-tests (i, j). n indicates the number of human specimens or mice per group. NS = non-significant. P < 0.001 or P < 0.0001
are represented as *** or ****, respectively.
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Figure 6. Neutralising IL-33 attenuates OA. (a, b) OARSI scoring of cartilage tissue, (c) synovitis scoring and (d) osteophyte maturity scoring of
sham-operated (n = 20) or DMM-operated (n = 20) WT mice (12 weeks post-surgery end timepoint) treated intraperitoneally with either IgG1
(vehicle control; 15 µg per mouse; daily for 12 weeks post-surgery) or aIL-33 (15 µg per mouse; daily for 12 weeks post-surgery). (e) von Frey pain
assessment of sham-operated (n = 20) or DMM-operated (n = 20) WT mice (12 weeks post-surgery end timepoint) treated intraperitoneally with
either IgG1 (vehicle control; 15 µg per mouse; daily for 12 weeks post-surgery) or aIL-33 (15 µg per mouse; daily for 12 weeks post-surgery). (f)
mRNA expression of cartilage degrading proteases (MMP-13, ADAMTS-5 and MMP-3) and chondrogenic markers (COL2A1, SOX-9 and Aggrecan)
in whole knee joints of DMM-operated (n = 20) treated intraperitoneally with either IgG1 (vehicle control; 15 µg per mouse; daily for 12 weeks
post-surgery) or aIL-33 (15 µg per mouse; daily for 12 weeks post-surgery). (g) protein and (h) mRNA expression of cartilage degrading proteases
(MMP-13, ADAMTS-5 and MMP-3) and chondrogenic markers (COL2A1, SOX-9 and Aggrecan) in isolated human chondrocytes from Non-OA
(n = 20) and OA patients (n = 20) treated with rIL-33 (30 ng mL1, 24 h) and IgG1 (vehicle control; 10 lg mL1, 24 h) or aIL-33 (10 lg mL1,
24 h). (i) MMP-13 (j) MMP-3 protein level in cell media supernatants obtained from isolated human chondrocytes from Non-OA (n = 12) and OA
patients (n = 12) treated with rIL-33 (30 ng mL1; 24 h) and IgG1 (vehicle control; 10 lg mL1, 24 h) or aIL-33 (10 lg mL1, 24 h). All RT-qPCR
gene expressions were normalised to the endogenous level of 18 s in respective groups. Data are expressed as mean  S.E.M. with two-way
analysis of variance followed by the Tukey-Kramer test (b, c, d) or repeated measures 2-way ANOVA with Bonferroni’s post hoc tests was used to
compare groups at each time point (e; DMM IgG1 control mice vs DMM aIL-33 mice) or with unpaired 2-tailed Student’s t-tests (i, j). n indicates
the number of human specimens or mice per group. NS = non-significant. P < 0.0001 is represented as ****.
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transection model may further substantiate our
findings. A further limitation of our study was not
using a spontaneous ageing model of OA. IL-33
signalling has been shown to be involved in the
exacerbation of age-related diseases.7 In
speculation, our data suggest it is plausible for IL-
33 signalling to be detrimental to cartilage
homeostasis during ageing. In addition, we could
not access osteophyte formation and bone
changes during disease development in mice
using micro-CT analysis. Hence, the role of IL-33
and ST2 in an aged joint and other joint tissues
still need to be further investigated.
To our knowledge, this is the first time
neutralising IL-33 and ST2 has been demonstrated
to reduce OA and pain in vivo. These results show
that IL-33 and ST2 blockade may also be an effective
analgesic for OA. A study by Zarpelon and
colleagues demonstrated carrageenin-induced paw
oedema and hyperalgesia were reduced in ST2 KO
mice.28 Further studies on the relationship between
IL-33 and local and systemic pain signalling
networks in anOA joint should be conducted.
In conclusion, we report that IL-33 and its
receptor ST2 are expressed in human and mouse OA
chondrocytes. Our findings indicate that IL-33 is
produced locally in OA joints by chondrocytes and
not synovial fibroblasts. Administration of
neutralising IL-33 and ST2 antibodies attenuated
the severity of OA and pain in vivo and was
associated with a marked decrease in the
production of cartilage-degrading proteases
alongside an increase expression of chondrogenic
markers. Neutralisation of IL-33 signalling may
prove to be a therapeutic option for OA (Figure 7).
METHODS
Human samples
Healthy or OA knee/hip cartilage, SF and serumwere obtained
from OA patients at The Second Hospital of Nanjing. OA
patients were a mix of both females and males (age range
from 42 to 79) and were either undergoing either hip or knee
replacement surgery. Non-OA samples were obtained from
patients who had undergone surgery for tumors of the lower
leg in which the knee joint was not affected males (age range
from 39 to 76). Tissue samples were collected with informed
written consent in full compliance with Declaration of
Helsinki and approval of the Ethics Committee of The Second
Hospital of Nanjing. All samples were transferred to the
laboratory within 2 h. Dissected cartilage pieces were
incubated overnight in Dulbecco’s modified Eagle’s medium
(DMEM; Lonza, Basel) with 1 mg mL1 Collagenase A (Roche
Pharmaceuticals, Basel) at 37°C for 5–6 h to isolate
chondrocytes. Cells used in experiments were at passage 1.
Serum was obtained from whole blood by centrifugation at
1600 g for 15 min at 20°C. Synovial fluid (SF) was centrifuged
for 20 min at 3000 g. Serum and SF were stored at 80°C
before experimentation.
Cell culture
Isolated human chondrocytes were cultured in DMEM
media containing 4.5 g L1 of glucose and L-glutamine
(Lonza). DMEM was supplemented, unless stated otherwise
with 10% foetal calf serum (FCS; Lonza), 1% Penicillin and
Streptomycin (Lonza), Amphotericin B (Gibco, Waltham)
and 2% (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
solution (Lonza). Cells were maintained under sterile
conditions in a humidified atmosphere of 37°C containing
95% oxygen and 5% (v/v) carbon dioxide unless stated
otherwise.
In vitro treatments
Isolated human chondrocytes were cultured to confluence,
serum starved with 1% FCS DMEM media for 1 h and then
treated with either PBS (Thermo Fisher Scientific, Waltham)
vehicle control or human recombinant (r)IL-33 (30 ng mL1;
PeproTech) for 24 h. For some experiments, IgG1 isotype
control (3 lg mL1 or 10 lg mL1; Sigma-Aldrich, St. Louis)
or human neutralising antibody (a)ST2 (3 lg mL1; R&D
Systems, Minneapolis) or aIL-33 (10 lg mL1; R&D Systems)
was added alongside human rIL-33 (30 ng mL1) for 24 h.
RNA analysis of human cells
Total RNA was isolated from human cell cultures using
RNeasy mini kit (Qiagen, Hilden) and reverse transcribed
using a High Capacity reverse transcription cDNA kit
(Applied Biosystems, Foster City) according to the
recommendations of the manufacturer. RT-qPCR was carried
out on a Real-Time PCR System (Zeesan systems, Xiamen).
Relative gene expression was analysed by the ΔΔCt method
using 18S as an endogenous control gene and TaqMan
probes (Supplementary table 1).
Mice
All animal procedures were approved by local ethics
committee. Male mice weighed 18–25 g and were
maintained in cages under controlled temperatures (19–
23°C) and lights (12-h light, 12-h dark cycle). All mice had
ad libitum access to water and chow. C57BL/6J (Charles
River, Wilmington) wild-type (WT) mice were used unless
otherwise stated.
Generation of synovial fibroblast- and
cartilage-specific IL-33 conditional KO mice
Male mice carrying a floxed IL-33 allele (IL-33fl/fl; Jackson
Laboratory, Bar Harbor) were bred with homozygote mice
carrying transgenes for COL1A2 Cre-ERT2 (Jackson
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Laboratory) or Aggrecan Cre-ERT2 (Jackson Laboratory).
Hence, we generated two different types of homozygote
double transgenic tissue-specific conditional knockout (KO)
mice. (1) IL-33fl/fl; COL1A2 Cre-ERT2 (IL-33COL1A2 Cre-ERT2) that
are synovial-specific IL-33-conditional KO mice. (2) Aggrecan
Cre-ERT2 (IL-33Acan Cre-ERT2) that are cartilage-specific IL-33-
conditional KO mice. Mice were obtained at the expected
Mendelian ratio with no adverse phenotypic side effects.
Adult mice (8 weeks of age) were administered
intraperitoneal doses of free base tamoxifen (TX) (2 mg kg1;
Sigma-Aldrich) three times every other day for one week to
induce conditional KO of IL-33. IL-33fl/fl mice were used as
controls for conditional KOmice unless otherwise stated.
Experimental OA
Murine OA was induced by using the destabilisation of the
medial meniscus (DMM) model.29 10-week-old male mice
were anaesthetised. The medial meniscus was identified, and
the attachments of its anterior horn to the tibial plateau were
cut. For sham control limbs, the mice were anaesthetised and
prepared as before. The right knee was opened using the
same medial para-patellar approach and the meniscus
identified, but the menisco-tibial ligament was not released.
The incisionwas closed, and themice recovered as before. Left
(contralateral) knees for both sham and DMM operations
were left as un-operated controls.
Pain assessment
Pain associated with OA was measured in mice using the
von Frey test and the hot plate assay as previously
described.30 Pain tests were conducted three times before
sham or DMM surgery and then once every two weeks after
surgery. For the hot plate assay, a surface of 55  0.5°C was
used with a latency period (cut-off) of 30 s defined as
complete analgesia. For the von Frey test, mice were
allowed to acclimate for at least 15 min before mechanical
allodynia was tested by touching the plantar surface of the
hind paw with von Frey filaments in ascending order of
force for up to 6 s.
In vivo treatments
For experiments which increased IL-33 levels in vivo, mouse
rIL-33 (Enzo Life Sciences, Farmingdale) was administered
intraperitoneally (i.p) on a daily basis at 33 lg kg1 for
12 weeks post-surgery. PBS was used as vehicle control in
experiments. For blocking IL-33 and ST2 signalling, mouse
aIL-33 (15 µg per mouse) or mouse aST2 (50 µg per mouse)
antibodies (R&D Systems) were dissolved in sterile PBS and
injected in respective groups of mice daily via i.p. Isotype
control IgG1 (Sigma-Aldrich) was dissolved in sterile PBS
and injected daily via i.p in mice at respective doses of each
neutralising antibody.
Extraction of murine tissues post-DMM
surgery
Whole blood was extracted from mice at 12 weeks post-
surgery left to clot at room temperature for 15 min, then
centrifuged at 3000 g for 10 min to obtain serum. SF was
extracted from culled mice (12 weeks post-surgery) by
injecting sterile PBS into the knee joint, then extracting the
fluid. Knee joints were harvested by excising at the
proximal femur and distal tibia. The skin and surrounding
muscles were then removed without disturbing the joint
and its associated ligaments. Knee joints were fixed in 10%
neutral buffered formalin for at least 24 h before any
further processing.
Histology
The specimens were decalcified in 20% formic acid for
14 days. The knees were then processed as per standard
protocol: 2 changes of formalin (40°C) followed by 70%
alcohol (40°C), 90% alcohol (40°C), 3 changes of absolute
alcohol (40°C), 4 changes of xylene (40°C) and 4 changes
of paraffin wax (60°C) with each change lasting 1.5 h.
The knees were then embedded in paraffin wax.
4-lm-thick coronal sections were cut and stained with
Safranin-O.
Disease scoring
Cartilage destruction was scored by two blinded observers
using the OARSI grading system. Briefly,31 a minimum of 6
sections were scored per joint. All four quadrants of the
knee were individually scored (medial femoral condyle and
tibial plateau, lateral femoral condyle and tibial plateau).
The summed score was calculated from the sum of the
Figure 7. Blockade of IL-33 signalling attenuates OA. IL-33 is produced locally in OA joints by chondrocytes. Neutralising IL-33 and ST2
antibodies attenuates the severity of OA and pain in vivo and decreases the production of cartilage degrading proteases.
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three highest scoring section totals (obtained from the sum
of all four quadrants per section). This provides an
indication of both severity and extent of OA damage
within the joint. There was no significant difference in the
scores between the two blinded scorers. Synovitis was
determined by grading synovial inflammation (grade 0–3)
as previously described.32 Osteophyte maturity (grade 0–3)
was quantified as previously described.33
Extraction of murine cartilage protein
Hips from young mice at 7 weeks of age are cartilaginous
and have adequate protein when pooled together (4
hips = 1n). These pooled hips were used to validate
efficient knockdown of IL-33 protein in conditional
cartilage-specific KO mice. Mice were injected with TX at
5 weeks of age and culled at week 7. Hips were avulsed
and placed in ice-cold protein lysis buffer (Sigma-Aldrich;
see Western blot analysis below). Thereafter, samples were
shaken for 2 h at 4°C. The samples were then centrifuged
at 13 000 9 g for 5 min at 4°C, and the supernatants were
collected for experiments. Immunoblotting was performed
on the collected supernatants as described below.
RNA analysis of murine tissues
Validation of efficient knockdown of IL-33 mRNA
expression in conditional cartilage specific KO mice was
performed on microdissected cartilage pooled from 4
mouse knee joints (1n). Briefly, mice were injected with TX
at 8 weeks of age and culled at week 10. Cartilage was
microdissected and stored in RNAlater stabilisation
solution (Life technologies, Carlsbad) at 80°C, whereas
whole knee joints for RNA analysis were exercised as stated
above then stored for RNAlater stabilisation solution (Life
technologies) at 80°C for experimentation.
Samples were placed in TRIzol (Life technologies), were
homogenised, shaken for 10 min at room temperature and
then centrifuged at 13 000 9 g for 10 min at 4°C.
Supernatants were diluted in an equal amount of 1-Bromo-
3-chloropropane (Sigma-Aldrich), vortexed and centrifuged
13 000 9 g for 15 min at 4°C. The upper aqueous phase
was removed and placed in new Eppendorfs. Thereafter,
the RNeasy microkit (Qiagen) protocol was followed for
microdissected cartilage and the RNeasy mini kit (Qiagen)
according to the manufacturer’s guidelines. RT-qPCR was
carried out as mentioned above.
Extraction of synovial fibroblasts and
culture
Murine synovial fibroblast isolation and culture was
adapted from previously published protocol.34 Briefly, the
articular cavity murine knee joints were cut open along
both sides of the patella under a microscope to isolate the
intra‑articular synovium carefully. Thereafter, the
connective tissues around the synovium were carefully
eliminated under a microscope. The synovium was finely
chopped in DMEM media and 0.5 mL 1% type IV
collagenase (Thermo Fisher Scientific) and incubated at a
constant temperature of 37˚C in an orbital shaker incubator
(200 rpm) for 60 min. Samples were vortexed vigorously for
1.5 min to release the cells. The samples were centrifuged
for 5 min at 3000 9 g and resuspended with DMEM
supplemented with 10% FCS and 1%
penicillin‑streptomycin. The cells were seeded and cultured
(37˚C, 5% CO2) until confluence for RNA and protein
extraction. Intra‑articular synovium of 10 murine knee joints
had to be pooled together for 1n.
Western blot analysis
Tissue or cell samples were homogenised in lysis buffer
(RIPA buffer) (Sigma-Aldrich), Ethylenediaminetetraacetic
acid (EDTA)-free protease inhibitor (Roche Pharmaceuticals),
phosphatase inhibitor cocktail 2 and 3 (Sigma-Aldrich) and
protein levels quantified by bicinchoninic acid (BCA) assay
(Thermo Fisher Scientific). Samples were probed overnight
with primary antibody: IL-33 (~ 30 kDa; 1:100; Novus
Biologicals, Littleton; NBP1-75516), ST2 (~ 50 and ~ 60 kDa;
1:100; Novus Biologicals; NBP2-53096), MMP-13 (~ 60 kDa;
1:100; Abcam, Cambridge; ab39012), ADAMTS-5 (~ 73 kDa;
1:100; Abcam; ab41037), COL2A1 (~ 141 kDa 1:1000; Sigma-
Aldrich; SAB4500366) and b-actin (loading control)
(~ 42 kDa; 1:20 000; Sigma-Aldrich; A2228).
Immunohistochemistry
Heat-mediated antigen retrieval was performed on
paraffin-embedded sections using citric acid buffer (Sigma-
Aldrich) warmed in a water bath at 100°C for 20 min. MMP-
13 (Abcam) antibody, COL2A1 (Sigma-Aldrich) antibody and
rabbit IgG control antibody (Sigma-Aldrich) were used at
1:200 dilution. Quantification of positive cells/total cells was
counted by two blinded operators.
ELISA
Stored supernatants or SF were defrosted at room
temperature, and MMP-13 and MMP-3 concentrations were
measured via ELISA (R&D Systems). Assays were conducted
as per the manufacturer’s instructions. Each ELISA sample
was measured twice, and the average was used to plot the
data (CV < 9%). ELISA experiments were conducted by
blinded experimenters.
Data analysis
All data are expressed as mean  standard error of mean
(S.E.M.) of n observations. Experiments were statistically
analysed utilising the Student’s unpaired two-tailed t-test
or analysed with two-way analysis of variance followed
by the Tukey-Kramer test or repeated measures 2-way
ANOVA with Bonferroni’s post hoc tests. A significant
difference was accepted when P < 0.05, P < 0.01,
P < 0.001 or P < 0.0001 represented in all tables and
figures as *, **, *** or ****, respectively. Data analysis
was performed using GraphPad Prism 5.0 (GraphPad
Software, California).
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